Development
The following charts summarize the dramatic improvement in hemostasis seen to date in animal testing.
The chart above shows the improvement of AC5® Surgical Hemostatic Device over both a control substance and a control peptide.
The last chart shows the improvement of AC5® Surgical Hemostatic Device over both cautery and saline control substances.
This chart shows how quickly AC5® stops bleeding in preclinical studies. The barely discernable green bars illustrate the time required for AC5® to achieve hemostasis (bleeding stopped) compared to the control times in red.
Sources:
- Ellis-Behnke RG, Liang YX, Tay DKC, Kau PWF, Schneider GE, Zhang S, Wu W and So KF. (2006) Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomedicine 2: 207-15.
- Comments in Science, JAMA, Nature Biotechnology, Nature nanomedicine, etc.
- Ellis-Behnke RG. (2011) At the nanoscale: nanohemostat, a new class of hemostatic agent. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 3: 70-8.